BioBiz Buzz
BioBiz Buzz offers exclusive insights into the biotech, pharma, and medtech industries through interviews with top executives and visionaries.
Providing thought-provoking podcasts covering topics such as scientific advancements, emerging technologies, and market trends, to keep listeners informed about the latest developments in life sciences.
Disclaimer
https://biobizbuzz.com/disclaimer/
BioBiz Buzz
27. Microbiome Medicines at Scale: MRM Health’s Mission to Redefine Immune-Mediated Disease
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
In this episode of BioBiz Buzz, Mike Ward talks to Dr Sam Possemiers, founder and CEO of Belgium-based MRM Health, about what it really takes to turn the human gut microbiome into a bona fide drug modality. They trace the arc from crude faecal microbiota transplants and limited single-strain probiotics to rationally designed consortia of commensal bacteria that function as a single, scalable therapeutic product.
Moreover, Possemiers explains how MRM Health’s Coral platform starts with patient-derived microbiome data, selects and “team-builds” core strains, and then does what has stumped many peers: manufactures an entire consortium, up to 30 strains, as one GMP-compliant drug substance in a single fermentation run. The conversation dives into lead candidate MH002, which combines six strains to restore microbial functions, reinforce barrier integrity and modulate immune pathways in ulcerative colitis and pouchitis, with early clinical data showing remission signals, microbiome recovery and a clean safety profile.
The conversation also explores the fast-track FDA-backed Starfish UC Phase 2b trial, an orphan-disease strategy in pouchitis, and pipeline programmes in immuno-oncology and broader inflammatory indications where microbiome modulation could boost checkpoint inhibitor responses or address disease root causes.
● Feedback
● Subscribe (Get notified when new episodes are available. NO marketing!)